SUMMARY In a study on 857 infants born preterm, high peak plasma alkaline phosphatase activity was independently related to slower growth rate in the neonatal period, and to a highly significant reduction in attained length at 9 months and 18 months post term. At 18 months the deficit in body length associated with peak neonatal plasma alkaline phosphase activity of 1200 IU/l or more was 1 6 cm (95% confidence interval 0-9 to 2-3 cm) after adjusting for confounding factors. The strength and magnitude of this association between high plasma alkaline phosphase activity and body length was greater than that for any other factor identified, including the infant's sex and the presence of fetal growth retardation. Data are presented that support the view that the high plasma alkaline phosphatase activity reflected early bone mineral substrate deficiency resulting in metabolic bone disease.
SUMMARY In a study on 857 infants born preterm, high peak plasma alkaline phosphatase activity was independently related to slower growth rate in the neonatal period, and to a highly significant reduction in attained length at 9 months and 18 months post term. At 18 months the deficit in body length associated with peak neonatal plasma alkaline phosphase activity of 1200 IU/l or more was 1 6 cm (95% confidence interval 0-9 to 2-3 cm) after adjusting for confounding factors. The strength and magnitude of this association between high plasma alkaline phosphase activity and body length was greater than that for any other factor identified, including the infant's sex and the presence of fetal growth retardation. Data are presented that support the view that the high plasma alkaline phosphatase activity reflected early bone mineral substrate deficiency resulting in metabolic bone disease.
We speculate that even silent early bone disease may interfere with the control of subsequent linear growth and emphasise the potential importance of providing preterm infants, especially those fed human milk, with adequate substrate for bone mineralisation.
Metabolic bone disease in preterm infants is common.' Though this has often been described as 'rickets', current evidence suggests that in most cases it is caused by a deficiency of mineral substrate rather than of vitamin D. 4 It is particularly common in very preterm infants who are being fed on breast milk.5 In most instances metabolic bone disease is not associated with obvious clinical signs, and the diagnosis has been based on radiographs, photonabsorptiometry, and biochemical changes including high plasma alkaline phosphatase activity. There is little information about whether such asymptomatic bone disease is benign or The principal objective in this paper was to relate plasma alkaline phosphase activity to neonatal and later growth. Data on the effects of diet on plasma alkaline phosphatase activity and growth are included here only to add weight to the argument that high neonatal alkaline phosphatase activity reflects metabolic bone disease.
Extensive data were collected on obstetric, perinatal, and postnatal events, including the following growth measurements in the neonatal period: body weight (daily to the nearest 1 g on an electronic balance, Sartorius MP series); occipitofrontal head circumference (twice weekly to the next succeeding 1 mm using paper tape); and crown-heel length (once or twice weekly to the next succeeding 1 mm using a horizontal stadiometer). Weight gain (g/kg/ day) was calculated from the age when birth weight had been regained. Head growth and length gain were calculated by a similar analysis of measurements made over a period of at least two weeks after regaining birth weight.
Blood samples were drawn weekly at the time of routine monitoring from all infants during their stay in hospital. Plasma calcium concentrations were measured by atomic absorption spectrophotometry and phosphorus was determined by an end point method on 5 ,ul of plasma using a direct phosphomolybdate reaction without deproteinisation (Smith, Kline Instrument Co Ltd). Alkaline phosphatase activity was measured kinetically on 2-5 I,l plasma by the catalysed hydrolysis of p-nitro-phenylphosphate to p-nitrophenol and phosphoric acid (Roche Products Ltd).
All surviving infants from three centres (Cambridge, Ipswich, and King's Lynn) were invited for follow up examinations at 9 months post term, and children from all five centres were examined at 18 months post term. Measurements of weight, crown-heel length, and occipitofrontal head circumference were included at these examinations '. Statistical analysis was by the x2 test, Student's t test, and regression analysis.
Results
Details of the study population are shown in table 1. The group has been divided into two according to peak plasma alkaline phosphatase activities (¢1200 IU/l). The value of 1200 IU/1, was chosen because, as described below, this was shown to be the cut off point that best discriminated between two groups of infants in terms of their growth performance. ASSOCIATION satisfactory measure of active metabolic bone disease in such studies." We provide here further strong evidence that high plasma alkaline phosphatase activity was related to bone mineral substrate deficiency. Analysis of raw data showed that infants with high peak plasma alkaline phosphatase activity (>1200 IU/1) had a higher incidence of low plasma and urinary phosphorus concentrations (minimum recorded values less than 1 -0 mmol/l, and 0*02 mmol/Il, respectively), and a higher incidence of hypercalcaemia (peak plasma calcium concentration more than 3*0 mmol/l), each suggesting low phosphorus intake or phosphorus deficiency (table 2). These fig 3 (a) . At 18 months the association between high neonatal alkaline phosphatase activity and reduced attained length was stronger and ofgreater magnitude than any other factor identified, which included being female, small for gestational age, or a twin. There was also an association between shorter stature and being fed on human milk in the neonatal period, which seemed to be independent of the association between diet and early bone disease. These associations are shown graphically in fig 3 (b) .
The magnitude of the reduction in body length at 18 months associated with a peak neonatal alkaline phosphatase activity of 1200 IU/I or more was 1-6 cm (95% CI 0-9 to 2-3 cm).
When adjustment was made for confounding factors there was no significant association between high alkaline phosphatase activity and gain in weight or head circumference in the newborn period, though there was a strong trend towards a negative association with weight gain, nor was any association with body weight or head circumference found at 9 and 18 months.
Discussion
High neonatal plasma alkaline phosphatase activity in low birthweight infants was strongly associated with impaired linear growth (reduced length gain in the neonatal period) and, of most importance, smaller attained length at 9 and 18 months corrected age. After adjusting for a wide range of potentially confounding factors, high neonatal plasma alkaline phosphatase activity (1200 IU/I or more) emerged as the major factor relating to stature at 18 months. At this age the deficit in length associated with high plasma alkaline phosphatase activity was 1-6 cm, corresponding to more than half a standard deviation for body length in healthy 18 month old children.
Other factors shown to be independently associated with length at 9 or 18 months were sex, being small for gestational age, or a twin (or triplet). There was also an independent association between reduced attained length at 18 months and exclusive human milk feeding, even after adjusting for the effect of this diet on the incidence of metabolic bone disease. Thus for either sex, singleton infants who were an appropriate weight for gestation, fed on a formula, and with a peak plasma alkaline phosphatase activity of less than 1200 IU/l, has a mean length at 18 months close to the 50th centile. In contrast, infants falling into the opposite categories, were estimated to be nearly 4 cm shorter (fig 2) , with a mean length near the third centile for an infant born at full term. Maternal pre-eclampsia, which has been reported to cause congenital rickets12 was not found to be associated with reduced linear growth. This does not rule out, however, an important effect of pre-eclampsia on neonatal mineral homoeostasis and later growth. Such an effect might be entirely subsumed into the effect of being small for gestational age.
A significant association between high alkaline phosphatase activity and reduced short and longer term linear growth was found whether peak alkaline phosphatase was treated as a continuous variable or a dichotomous one. More detailed analysis, however, showed minimal change in linear growth with peak alkaline phosphatase values up to 1000 IU/l, and a precipitous reduction in linear growth if the peak alkaline phosphatase activity was above 1200 IU/I. Thus we suggest that, for prognostic purposes, it is most useful to treat alkaline phosphatase as a dichotomous variable with 'high' and 'low' values above and below 1200 IU/l.
It is important to consider what a raised plasma alkaline phosphatase activity means, as doubt has been thrown on its value as an indicator of metabolic bone disease in low birthweight infants. '3 14 Such doubts have been mainly concerned with its specificity as an indicator of active bone disease at a particular point in an infant's clinical course, and several workers have found values that were not grossly increased at times when there was radiological evidence of frank bone disease.13 15 16 The biology of alkaline phosphatase has been reviewed by Anderson.17 The enzyme is located on the membrane of osteoblast derived 'matrix vesicles', and in parent osteoblasts is close to the mineralisation front. Current evidence suggests that membrane phosphatase is a phosphotransferase, which transfers phosphate residues into matrix vesicles, wheretogether with trapped calcium ions-they initiate crystallisation. As Our data add further weight to the view that high plasma alkaline phosphatase activity is associated with bone mineral substrate deficiency. In a randomised comparison infants fed human milk had significantly higher plasma alkaline phosphatase activity than those receiving a formula providing twice the calcium and phosphorus contents of breast milk (fig 1) . The human milk fed group showed further evidence of phosphorus depletion, with a significantly higher incidence of hypophosphataemia and low urine phosphorus concentrations. Moreover, high alkaline phosphatase activity itself was associated with hypophosphataemia, low urinary phosphorus concentrations, and an increased incidence of hypercalcaemia, which has been described with phosphorus depletion.28 29 Regardless of the debate on whether high plasma alkaline phosphatase activity is a valuable neonatal screening test for metabolic bone disease in individual preterm infants, we have shown that it is an important indicator of outcome in terms of later linear growth. Few previous studies have related early bone disease to long term outcome; work in this field has focused mainly on identification and quantification of active bone disease. Metabolic bone disease in preterm infants, however, is usually asymptomatic and is frequently missed. Indeed, in this investigation high plasma alkaline phosphatase activity often occurred when the baby was well, and might have been overlooked had the infant not been taking part in a scientific study. We suggest poor linear growth performance both in the short and longer term could be viewed as an important, adverse, clinical outcome response to even silent early metabolic bone disease. We speculate also that the trend towards reduced neonatal weight gain seen with increased plasma alkaline phosphatase activity is linked to the effects of phosphorus depletion on soft tissue growth and metabolism. 30 Though we have shown that high alkaline phosphatase activity relates well to these adverse responses, it is pertinent to note that other tests for metabolic bone disease, namely radiographs of long bones and photonabsorptiometry, as yet have unknown predictive value for later outcome. Furthermore, radiography and densitometry both include irradiation of the patient.
Our hypothesis, strongly supported by the data presented, that neonatal metabolic bone disease has a long lasting and important effect on linear growth, is perhaps a surprising one as excellent catch up is usually seen during the treatment ofclassical rickets. 3' Early bone disease in preterm infants seems increasingly unlikely to be a vitamin D related problem in most cases1 so cannot be directly compared with classical rickets. Even so, if we assume that the cause of metabolic bone disease in primarily a deficiency of bone mineral substrate, it still requires explanation that catch up growth and a return to normal growth velocity do not apparently take place once calcium and phosphorus intake and absorption have reached normal infant values32 and the bones have remineralised. 33 We have considered that our findings could be explained by some completely different and as yet unidentified confounding factor or factors that were associated with early bone disease and had a continued influence on growth. Arguably it is difficult to adjust statistically for the variable degree of illness seen in preterm infants. We 
